USP 232 and 233 testing | Materials Metric | Trace Metals

What Is USP 232 and 233 Testing — and Why Does It Matter?

USP 232 and 233 testing defines the regulatory framework for measuring elemental impurities in pharmaceutical products, ensuring patient safety by setting strict permissible daily exposure (PDE) limits for toxic metals. Together, these two chapters from the United States Pharmacopeia (USP) specify which elements must be controlled and exactly how laboratories must validate the procedures used to detect them. Consequently, any drug product sold in regulated markets must demonstrate compliance with both chapters before it reaches patients.

Furthermore, these standards now apply across a remarkably broad scope — from small-molecule drug substances and excipients to biologics, inhalation products, and parenteral formulations. In addition, the chapters align closely with the International Council for Harmonisation guideline ICH Q3D, making them globally recognized benchmarks. As a result, manufacturers operating in the US, EU, and many other jurisdictions rely on USP 232 and 233 testing as a cornerstone of their quality and regulatory strategies.

However, meeting these requirements is not simply a matter of running one instrument analysis. Specifically, laboratories must navigate element classification, route-of-administration thresholds, sample preparation protocols, and full analytical method validation. This guide explains every key aspect — from the underlying science to practical compliance steps — so engineers, quality managers, and regulatory teams can approach USP 232 and 233 testing with confidence.

Key Takeaways

• USP General Chapter <232> sets PDE limits for elemental impurities in pharmaceutical products across three oral, parenteral, and inhalation routes of administration.
• Meanwhile, USP General Chapter <233> prescribes the analytical procedures — primarily ICP-MS and ICP-OES — and full validation requirements for measuring those impurities.
• Compliance requires risk-based assessment, method development, and validated analytical data before any regulatory submission.
• ICH Q3D alignment means these limits are recognized by the FDA, EMA, and most global health authorities.
• Laboratories must validate procedures for accuracy, precision, specificity, and limit of quantitation, among other parameters.
• Materials Metric provides end-to-end Chemical & Analytical Testing services tailored to USP 232 and 233 compliance.

USP 232 and 233 testing: A United States Pharmacopeia regulatory framework in which General Chapter <232> establishes route-specific permissible daily exposure limits for elemental impurities in drug products, and General Chapter <233> defines the validated analytical procedures — chiefly ICP-MS and ICP-OES — that laboratories must use to demonstrate compliance with those limits.

Key fact: Elemental impurities — including lead, arsenic, cadmium, and mercury — are among the most toxicologically significant contaminants in pharmaceutical manufacturing, and even trace-level exposures can accumulate over a patient’s lifetime of drug use. Consequently, regulatory agencies worldwide treat elemental impurity control as a primary patient-safety obligation, not an optional quality measure.

What Is USP General Chapter <232> and Which Elements Does It Cover?

USP General Chapter <232> — formally titled Elemental Impurities — Limits — establishes the maximum allowable daily exposure for specific elements that may appear in drug products. It classifies those elements into three groups based on their toxicological risk and likelihood of occurrence in pharmaceutical manufacturing. Therefore, understanding the classification system is the essential first step for any compliance program.

The chapter draws directly from USP General Chapter <232> Elemental Impurities and closely mirrors the ICH Q3D guideline. In addition, it applies to finished drug products — not just drug substances — which means every excipient, container closure, and processing aid in the formulation must be considered in the risk assessment.

The Three Classes of Elemental Impurities

Class 1 elements are the highest-concern group: lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As). These four elements have well-established human toxicity, and regulators consider their presence in drug products unacceptable above tightly defined PDE values. Consequently, Class 1 elements must always be assessed, regardless of the drug’s intended route of administration.

Meanwhile, the Class 2 group splits further into 2A and 2B sub-categories based on the likelihood of encountering them in pharmaceutical manufacturing. Cobalt, nickel, and vanadium fall into 2A, meaning they warrant routine monitoring. By contrast, Class 2B elements — such as silver, gold, and thallium — rarely appear in typical manufacturing scenarios and require assessment only if there is a specific reason to expect their presence.

By comparison, Class 3 elements present the lowest oral toxicity risk and include elements like barium, chromium, copper, lithium, and molybdenum. However, their PDE limits become significantly tighter for inhalation and parenteral routes. Therefore, the route of administration is always a critical variable when setting internal specification limits.

How Route of Administration Affects PDE Limits

The permissible daily exposure value for any given element depends heavily on how patients receive the drug. Oral products generally carry the least restrictive PDE limits because the gastrointestinal tract absorbs many heavy metals poorly. Parenteral and inhalation routes, however, deliver impurities directly into systemic circulation or lung tissue, so their limits are far more stringent.

For example, the oral PDE for lead is 5 µg/day, while the parenteral limit drops to 5 µg/day as well — but inhalation falls to just 5 µg/day with adjusted bioavailability factors applied. Furthermore, for elements like nickel, the difference between oral and inhalation limits spans an order of magnitude. As a result, product teams must clearly define the intended route before any analytical targets are set.

In addition, combination products or products with multiple delivery routes require assessment against the most stringent applicable limit. This complexity reinforces why Scientific & Technical Consulting early in development prevents costly reformulation later.

Risk Assessment as the Starting Point

USP <232> does not require blind testing of every element in every product. Instead, it mandates a structured risk assessment that evaluates each potential source of elemental contamination — drug substance, excipients, water, equipment, and container closure systems. This approach prioritizes analytical resources toward the elements most likely to be present.

Importantly, the risk assessment must consider known elemental composition of raw materials, historical supplier data, and manufacturing process information. Furthermore, any elemental impurity identified during the assessment at more than 30% of the relevant PDE must be included in the final control strategy. Teams engaged in risk-based biocompatibility testing will find this framework conceptually familiar, as both disciplines use structured hazard identification before committing to full analytical programs.

What Does USP General Chapter <233> Require for Analytical Procedures?

USP General Chapter <233> — Elemental Impurities — Procedures — specifies the analytical methods and validation requirements that laboratories must satisfy to generate defensible compliance data. It does not mandate a single instrument but strongly favors inductively coupled plasma–mass spectrometry (ICP-MS) and inductively coupled plasma–optical emission spectrometry (ICP-OES) as the primary techniques. Consequently, most pharmaceutical laboratories and contract testing organizations center their elemental impurity programs around one or both of these platforms.

Moreover, the chapter defines a rigorous validation framework that goes well beyond simply running a calibration curve. Laboratories must demonstrate that their procedure is suitable for its intended purpose across a defined concentration range, matrix type, and list of target elements. As a result, method validation under USP <233> is often the most time-consuming and documentation-intensive part of the entire compliance program.

Primary Analytical Techniques Used in USP 232 and 233 Testing

ICP-MS is the dominant technique in USP 232 and 233 testing because it offers exceptional sensitivity — detection limits in the parts-per-trillion range for most elements. This performance is essential for elements with very low PDE values, such as cadmium and mercury. Furthermore, modern ICP-MS instruments can measure dozens of elements simultaneously in a single run, making them highly efficient for multi-element compliance panels.

ICP-OES provides a complementary approach, particularly for elements present at higher concentrations or when matrix interferences complicate ICP-MS measurements. Specifically, it excels in robustness and throughput for routine monitoring once a method is established. Laboratories running Chemical & Elemental Characterization programs often use both techniques in a tiered strategy — ICP-OES for screening and ICP-MS for confirmation at lower levels.

Additionally, atomic absorption spectrometry (AAS) remains acceptable under USP <233> for specific single-element determinations, though it is less commonly deployed in modern compliance laboratories due to its lower throughput. XRF Analysis can also serve as a useful screening tool during risk assessment, though it does not typically meet the sensitivity demands of full USP <233> validation on its own.

Validation Parameters Mandated by USP <233>

USP <233> requires validation of six core analytical parameters. Each parameter serves a specific purpose in demonstrating that the method produces reliable, reproducible results at the concentrations relevant to pharmaceutical safety limits.

1. Accuracy: Demonstrated by spiking the sample matrix at 50%, 100%, and 150% of the target limit concentration. Recovery must fall within 70–150% across the spiking levels.
2. Precision: Assessed through repeatability (within a single session) and intermediate precision (across different days, analysts, or instruments). Acceptable %RSD targets apply at each concentration level.
3. Specificity: The method must distinguish the target elements from matrix interferences, isobaric overlaps, and any polyatomic species generated during plasma ionization.
4. Limit of quantitation (LOQ): Must be at or below 30% of the established PDE-derived control threshold for each element — ensuring the method detects impurities before they approach the regulatory limit.
5. Range: Demonstrated across the concentration interval from the LOQ to at least 150% of the control threshold.
6. Robustness: Evaluated by intentionally varying method parameters — such as digestion temperature, dilution factor, and plasma power — to confirm results remain stable under minor changes.

In addition, laboratories must document the reference standard preparation, calibration strategy, and internal standard selection. Thorough Method Development & Validation documentation is not just good practice — it is a regulatory expectation that auditors and reviewers will scrutinize closely.

Sample Preparation: Digestion and Matrix Considerations

Accurate elemental analysis begins long before the sample reaches the instrument. Sample preparation — typically microwave-assisted acid digestion — converts the pharmaceutical matrix into a clear aqueous solution suitable for ICP analysis. Therefore, the digestion protocol must completely dissolve all organic material without contaminating the sample or losing volatile elements like mercury.

Notably, different pharmaceutical matrices demand different preparation strategies. Solid oral dosage forms, liquids, semi-solids, and lyophilized biologics each present unique challenges in achieving complete digestion and consistent recoveries. Meanwhile, parenteral formulations often contain surfactants, proteins, or lipids that complicate both digestion and instrument introduction. Consequently, method development must validate the entire sample preparation workflow — not just the instrumental measurement step.

Teams handling complex formulations benefit greatly from pairing elemental analysis with Chemical Purity & Contaminant Screening to understand the full impurity profile before committing to a single analytical method. Furthermore, consulting published resources such as ScienceDirect – Analytical Methods provides valuable literature support for novel matrix challenges.

How Does USP 232 and 233 Testing Fit into the Broader Regulatory Landscape?

USP 232 and 233 testing does not exist in isolation. Instead, it forms one layer of a larger regulatory ecosystem that includes ICH Q3D, ISO standards, and FDA guidance documents. Understanding how these frameworks interact helps teams avoid redundant testing and ensures that data generated for one submission can support others efficiently.

For instance, the ICH Q3D guideline and USP <232> share the same PDE values and element classification structure. Therefore, a compliant USP <232> risk assessment typically satisfies ICH Q3D requirements simultaneously — a significant efficiency for companies pursuing approval in both US and international markets.

Alignment with ICH Q3D and International Standards

ICH Q3D was developed through collaboration between the FDA, EMA, and PMDA to harmonize elemental impurity controls globally. As a result, the PDE limits in USP <232> are numerically identical to those in Q3D, and the risk assessment logic follows the same stepwise approach. Manufacturers who invest in a rigorous ICH Q3D assessment typically find that USP <232> compliance follows naturally.

Moreover, for medical device and combination product manufacturers, ISO 10993-18 Chemical Characterization adds another dimension of elemental impurity assessment — specifically for materials that contact the body. Similarly, companies developing combination products must satisfy both the pharmaceutical elemental impurity requirements and the biocompatibility chemical characterization demands under ISO 10993. Our ISO 10993-18 compliance guide explores this intersection in greater depth.

FDA Expectations and Submission Requirements

The FDA expects pharmaceutical applicants to include a summary of their elemental impurity risk assessment and any analytical control data in new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics license applications (BLAs). Specifically, the agency looks for evidence that the applicant identified all relevant impurity sources, assessed them against route-appropriate PDE limits, and implemented validated controls where necessary.

Furthermore, the FDA may request the underlying raw data and method validation reports during review or inspection. Consequently, laboratories must maintain complete, traceable records of every calibration, spike recovery, and analytical run associated with the compliance program. Robust Chemical & Analytical Testing documentation practices are therefore inseparable from the technical work itself.

Connection to Biocompatibility and Toxicology Programs

Elemental impurity data generated through USP 232 and 233 testing often feeds directly into broader biocompatibility and toxicology assessments. For example, a leachables study on a container closure system may identify metal impurities that then require quantification against USP <232> PDE thresholds. Therefore, these programs benefit greatly from coordination between analytical chemistry and toxicology teams.

Additionally, risk-based biocompatibility frameworks — including those aligned with Biocompatibility & Toxicity Testing services — use elemental characterization data to determine whether formal in vitro or in vivo testing is warranted. In particular, research available through PubMed Central – Trace Metals Review continues to refine our understanding of metal toxicokinetics, informing how PDEs are interpreted in clinical context. For reusable device manufacturers, our article on reusable medical device testing covers how elemental analysis integrates with cleaning validation and residual contaminant assessment.

Advanced Analytical Techniques in USP 232 and 233 Testing

Modern USP 232 and 233 testing relies on a toolkit of complementary techniques, each suited to different elements, matrices, and sensitivity requirements. Selecting the right method — or combination of methods — is a critical decision that affects both data quality and regulatory defensibility. Therefore, understanding the strengths and limitations of each technique helps laboratories design efficient, fit-for-purpose compliance programs.

ICP-MS: The Gold Standard for Trace Elemental Analysis

Inductively coupled plasma–mass spectrometry (ICP-MS) dominates pharmaceutical elemental impurity testing for good reason. It routinely achieves detection limits in the parts-per-trillion range, covering the full panel of Class 1 and Class 2 elements in a single analytical run. Furthermore, collision cell and reaction cell technology in modern instruments effectively suppresses polyatomic interferences — a common challenge in complex pharmaceutical matrices.

Isotope dilution ICP-MS adds another layer of accuracy by using isotopically labeled internal standards to correct for matrix-induced signal suppression or enhancement. Consequently, this approach is particularly valuable for parenteral and biologic formulations where protein-rich matrices can significantly affect analyte recovery. Laboratories offering Chemical & Elemental Characterization services deploy ICP-MS as their primary quantification platform for USP <233> compliance work.

ICP-OES: Robust Screening and Mid-Level Quantification

ICP-OES measures elemental emission spectra generated when a sample is introduced into an argon plasma. It offers excellent robustness, wide linear dynamic range, and high throughput — making it well suited for elements present at mid- to high-concentration levels. However, its detection limits are typically two to three orders of magnitude higher than ICP-MS, so it cannot always reach the concentration thresholds required for the most sensitive elements.

Nonetheless, ICP-OES plays a valuable role in tiered testing strategies. For example, laboratories often use it for initial screening of raw materials and excipients, reserving ICP-MS confirmation for samples that approach or exceed the 30% PDE control threshold. In addition, ICP-OES handles high-matrix samples — such as those containing elevated calcium or sodium — more comfortably than ICP-MS in many workflows.

Complementary Techniques That Support USP 233 Programs

Beyond ICP-based methods, several complementary techniques add value at different stages of USP 232 and 233 testing. Cold-vapor atomic fluorescence spectrometry (CV-AFS) provides exceptional sensitivity for mercury — sometimes outperforming ICP-MS for this specific element. Meanwhile, hydride generation techniques improve detection of arsenic, selenium, and other hydride-forming elements by separating them from the matrix before measurement.

Screening tools such as XRF Analysis help teams rapidly identify heavy metal hotspots in solid materials during risk assessment, though XRF does not replace validated ICP methods for final compliance data. Similarly, HPLC Analysis coupled to ICP-MS (LC-ICP-MS) enables speciation of elements like arsenic and chromium — distinguishing toxic inorganic forms from less hazardous organic species. This distinction directly influences the toxicological risk assessment and PDE limit interpretation.

Research published in ScienceDirect continues to advance sample preparation strategies and instrumental approaches that improve matrix tolerance and reduce method development time for novel pharmaceutical formulations.

Industry-Specific Applications of USP 232 and 233 Testing

Although USP <232> and <233> formally apply to pharmaceutical drug products, the underlying principles — elemental impurity risk assessment and validated quantitative analysis — extend across multiple industries. Consequently, many organizations outside traditional pharma find these chapters highly relevant to their own regulatory and quality obligations.

Pharmaceutical Drug Products and Active Ingredients

The primary application remains the pharmaceutical sector, where finished drug products, drug substances, and excipients must all satisfy elemental impurity controls. Manufacturers of both synthetic small-molecule drugs and complex biologics must perform a risk assessment covering every raw material, processing step, and packaging component. In particular, botanical drug substances and mineral-derived excipients frequently carry elevated background levels of Class 2 and Class 3 elements that require careful quantification.

Contract development and manufacturing organizations (CDMOs) face an added layer of complexity — they must maintain validated USP <233> methods adaptable to diverse client formulations. Therefore, robust Method Development & Validation programs with transferable, matrix-flexible procedures are a significant competitive advantage in the CDMO space.

Medical Devices and Combination Products

Medical device manufacturers increasingly encounter USP 232 and 233 testing requirements when their products deliver drug substances or contact body fluids. Combination products — such as drug-eluting stents, prefilled syringes, and inhaler devices — must satisfy both pharmaceutical elemental impurity limits and device-specific chemical characterization demands. Furthermore, ISO 10993-18 requirements for chemical characterization of device materials often generate elemental data that feeds directly into the USP <232> risk assessment.

Device manufacturers working with metallic alloys, coatings, or adhesives benefit from early elemental characterization of all material components. Our article on extraction conditions explains how selecting appropriate extraction solvents and conditions ensures that leachable elemental impurities are accurately captured during compliance testing. Additionally, Biocompatibility & Toxicity Testing services integrate these elemental findings into the overall biological safety evaluation.

Nutraceuticals, Dietary Supplements, and Veterinary Products

While USP chapters <232> and <233> are written for pharmaceutical products, nutraceutical and dietary supplement manufacturers often voluntarily adopt the same framework to demonstrate product safety and quality. Mineral-containing supplements — calcium, iron, magnesium, and zinc formulations — present a particularly complex elemental matrix where trace impurities from raw material sources can quickly exceed pharmaceutical-grade PDE benchmarks if left uncontrolled.

Notably, the FDA’s increasing scrutiny of heavy metals in dietary supplements has prompted many manufacturers to align their internal specifications with USP <232> PDE limits. Consequently, Chemical & Analytical Testing services structured around the USP <233> validation framework provide these manufacturers with defensible, audit-ready data even outside a formal drug regulatory filing.

Quality Assurance and Best Practices for USP 232 and 233 Compliance

Technical competence in ICP-MS is necessary but not sufficient for a successful USP 232 and 233 testing program. Quality assurance practices — encompassing documentation, reference standard management, contamination control, and continuous method monitoring — determine whether regulatory agencies and auditors accept the data as reliable. Moreover, building these practices into the program from the outset prevents costly remediation during inspections or submissions.

Laboratory Controls and Contamination Prevention

Trace elemental analysis demands exceptional contamination control because the analytes of interest exist at parts-per-billion or parts-per-trillion concentrations. Even minor contamination from glassware, reagents, sample containers, or analyst contact can falsely elevate results and trigger unnecessary regulatory action. Therefore, laboratories must use ultra-high-purity acids, trace-metal-clean plasticware, and laminar-flow workspaces during sample preparation.

Procedural blanks — reagent blanks and method blanks — must accompany every analytical batch to confirm that the preparation process itself does not introduce measurable elemental contamination. In addition, certified reference materials (CRMs) with known elemental concentrations serve as independent accuracy checks alongside the spike recovery data required by USP <233>. Wet Chemistry & Classical Analytical Methods expertise also supports sample dissolution optimization when standard microwave digestion protocols perform inadequately for unusual matrices.

Reference Standards, Calibration, and Traceability

Calibration solutions must trace to primary reference standards — typically NIST-traceable single-element or multi-element stock solutions — to satisfy both USP <233> requirements and good laboratory practice expectations. Laboratories should maintain a clearly documented calibration hierarchy, from primary stock to working standards, with documented preparation records, expiry dates, and storage conditions. Consequently, any break in this traceability chain can invalidate an entire analytical dataset.

Internal standards — elements not expected in the sample, such as rhodium, indium, or iridium — compensate for short-term instrumental drift during an analytical run. Furthermore, bracketing calibration standards at the beginning and end of each sequence monitors long-term signal stability. These controls collectively ensure that quantitative data meets the accuracy and precision requirements defined in USP <233>.

Ongoing Method Monitoring and Change Control

Validated methods do not remain reliable without continuous monitoring. Control charts tracking spike recoveries, blank values, and instrument sensitivity over time provide early warning of method drift before it affects compliance data. As a result, laboratories should establish statistical control limits and review charts at defined intervals — typically with every analytical batch and in a formal periodic review.

Method changes — such as switching instrument models, modifying digestion parameters, or changing reagent suppliers — require formal change control and may trigger partial or full revalidation. Consulting resources such as USP Elemental Impurities guidance helps teams determine the scope of revalidation needed for specific change types. Engaging Scientific & Technical Consulting support during these transitions ensures that change control documentation meets regulatory expectations.

Quick note: Laboratories that proactively build control charts, batch acceptance criteria, and formal change control into their USP 233 programs from the outset consistently pass regulatory audits with fewer findings than those that retrofit quality systems after initial method validation.

Frequently Asked Questions About USP 232 and 233 Testing

What is the difference between USP <232> and USP <233>?

USP <232> sets the regulatory limits — specifically the permissible daily exposure values — for elemental impurities in pharmaceutical products. By contrast, USP <233> defines the analytical procedures and full validation requirements that laboratories must use to measure those impurities. Together, the two chapters form a complete compliance framework: <232> answers “how much is allowed,” and <233> answers “how do you measure it reliably.”

Does USP 232 and 233 testing apply to all pharmaceutical products?

USP <232> applies broadly to finished drug products intended for human use, including oral, parenteral, inhalation, and topical formulations. However, the specific elements assessed and the applicable PDE limits vary by route of administration. Furthermore, products manufactured and sold exclusively in non-USP markets may follow ICH Q3D rather than the USP chapters directly — though the numerical limits are identical, so the practical difference is minimal.

How long does USP 233 method validation typically take?

Validation timelines depend heavily on matrix complexity, the number of target elements, and whether a previously validated method can be adapted. For straightforward oral solid dosage forms using an established ICP-MS platform, validation commonly takes four to eight weeks from method development through final validation report. Complex biologics, inhalation products, or novel matrices frequently require additional development time — sometimes extending validation to twelve weeks or more. Early engagement with Method Development & Validation specialists accelerates this timeline considerably.

Can existing ICP-MS methods be transferred from one laboratory to another under USP <233>?

Yes — method transfer is explicitly addressed within the broader USP analytical procedure lifecycle framework. However, the receiving laboratory must demonstrate that it can reproduce the performance characteristics established during original validation, typically through an abbreviated inter-laboratory comparison study. Importantly, differences in instrument configuration, reagent sources, or local water quality can all introduce variability that requires documented assessment before the transferred method supports regulatory submissions.

What happens if an elemental impurity exceeds its USP <232> limit?

An exceedance triggers a formal out-of-specification (OOS) investigation to confirm whether the result reflects a genuine product quality issue or an analytical error. If confirmed, the manufacturer must identify the contamination source, assess patient risk, and implement corrective and preventive actions — which may include reformulation, supplier qualification, or enhanced in-process controls. Additionally, depending on the severity and affected batch size, regulatory reporting or market action may be required.

Is USP 232 and 233 testing required for excipients and packaging components?

Excipients and container closure systems are not independently subject to USP <232> limits — the chapter applies to the finished drug product. Nevertheless, the risk assessment mandated by <232> requires manufacturers to evaluate all input materials, including excipients and packaging, as potential elemental impurity sources. Therefore, obtaining elemental characterization data for excipients and packaging from suppliers — or generating it independently — is an essential part of a complete compliance program. Our extraction conditions article provides practical guidance on designing leachables studies for packaging components within this framework.

Conclusion

USP 232 and 233 testing represents one of the most technically demanding and consequentially important compliance obligations in pharmaceutical manufacturing. Together, these chapters create a science-based, risk-proportionate system that protects patients from elemental impurities while giving manufacturers a clear, internationally harmonized pathway to regulatory approval. Ultimately, success depends not just on instrumental capability but on the integration of rigorous risk assessment, validated analytical methods, and robust quality assurance practices.

Moreover, the scope of these requirements continues to expand as combination products, novel delivery systems, and complex biologics become more prevalent. Consequently, organizations that invest early in expert analytical partnerships — rather than treating elemental impurity testing as a late-stage checkbox — consistently achieve faster, more cost-effective compliance outcomes.

At Materials Metric, our team combines deep expertise in ICP-MS and ICP-OES methodology, pharmaceutical regulatory science, and quality system design to support every stage of your USP 232 and 233 testing program. From initial risk assessment through full analytical method validation and ongoing routine testing, we deliver defensible, audit-ready data that regulatory agencies accept with confidence. Furthermore, our Chemical & Analytical Testing and Chemical & Elemental Characterization capabilities are backed by Method Development & Validation expertise developed across hundreds of pharmaceutical, medical device, and nutraceutical projects.

If your organization needs support with elemental impurity compliance — whether for a new drug application, a combination product submission, or a supplier qualification program — contact Materials Metric today to discuss your specific needs and requirements with our technical team.

Related Posts from Materials Metric

Explore more insights from our team of materials scientists and analytical experts:

• Leachables risk assessment | Materials Metric | Chem Lab
• Extractables study design | Materials Metric | Chem Lab
• Chemical characterization cost | Materials Metric | Chem Lab
• Combination product characterization | Materials Metric